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ARTICLE OPEN
Randomized phase II trial of fulvestrant alone or in
combination with bortezomib in hormone receptor-positive
metastatic breast cancer resistant to aromatase inhibitors: a
New York Cancer Consortium trial
Kerin Adelson1, Bhuvaneswari Ramaswamy2, Joseph A Sparano3, Paul J Christos4, John J Wright5, George Raptis6, Gang Han7,
Miguel Villalona-Calero8, Cynthia X Ma9, Dawn Hershman10, Joseph Baar11, Paula Klein12, Tessa Cigler13, G Thomas Budd14,
Yelena Novik15, Antoinette R Tan16, Susan Tannenbaum17, Anupama Goel12, Ellis Levine18, Charles L Shapiro2, Eleni Andreopoulou3,
Michael Naughton9, Kevin Kalinsky19, Sam Waxman12 and Doris Germain12
The proteasome inhibitor bortezomib enhances the effect of the selective estrogen receptor (ER) downregulator (SERD) fulvestrant
by causing accumulation of cytoplasmic ER aggregates in preclinical models. The purpose of this trial was to determine whether
bortezomib enhanced the effectiveness of fulvestrant. One hundred eighteen postmenopausal women with ER-positive metastatic
breast cancer resistant to aromatase inhibitors (AIs) were randomized to fulvestrant alone (Arm A—500 mg intramuscular (i.m.) day
− 14, 1, 15 in cycle 1, and day 1 of additional cycles) or in combination with bortezomib (Arm B—1.6 mg/m2 intravenous (i.v.) on
days 1, 8, 15 of each cycle). The study was powered to show an improvement in median progression-free survival (PFS) from 5.4 to
9.0 months and compare PFS rates at 6 and 12 months (α= 0.10, β= 0.10). Patients with progression on fulvestrant could cross over
to the combination (arm C). Although there was no difference in median PFS (2.7 months in both arms), the hazard ratio for PFS in
Arm B versus Arm A (referent) was 0.73 (95% confidence interval (CI) = 0.49, 1.09, P= 0.06, 1-sided log-rank test, significant at the
prespecified 1-sided 0.10 α level). At 12 months, the PFS proportion in Arm A and Arm B was 13.6% and 28.1% (P= 0.03, 1-sided
χ2-test; 95% CI for difference (14.5%) =− 0.06, 29.1%). Of 27 patients on arm A who crossed over to the combination (arm C), 5 (18%)
were progression-free for at least 24 weeks. Bortezomib likely enhances the effectiveness of fulvestrant in AI-resistant, ER-positive
metastatic breast cancer by reducing acquired resistance, supporting additional evaluation of proteasome inhibitors in combination
with SERDs.
npj Breast Cancer (2016) 2, 16037; doi:10.1038/npjbcancer.2016.37; published online 14 December 2016
INTRODUCTION
Endocrine therapy prolongs survival in patients with metastatic
breast cancer whose tumors express the estrogen receptor (ER)
and is better tolerated than chemotherapy. Current options
include selective estrogen receptor modulators (e.g., tamoxifen),
aromatase inhibitors (e.g., anastrozole, letrozole, and exemestane),
and selective estrogen receptor downregulators (SERDs) (e.g.,
fulvestrant).1 However, resistance to endocrine therapy is a major
clinical challenge.2 Recently, several agents have been shown to
enhance the effectiveness of hormonal modulation, including the
mTor inhibitor everolimus,3 the CDK 4/6 inhibitor palbociclib,4 and
the histone deacetylase inhibitor entinostat,5 indicating that it
may be feasible to abrogate endocrine resistance with rational
combinations of endocrine and non-endocrine agents, including
those that have only modest activity when used alone.
Fulvestrant is a SERD that binds, inhibits, and degrades the
estrogen receptor (ER). It binds with 100-fold greater affinity than
tamoxifen, and more effectively inhibits estrogen signaling than
either tamoxifen or AIs6–8 suggesting that it may be a better
platform for combining with agents targeting other pathways. In
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addition to degrading the ER in the nucleus, fulvestrant has a
unique mechanism of action, which promotes the accumulation of
insoluble ER aggregates in the cytoplasm, activating a sustained
unfolded protein response, which leads to DNA fragmentation
and apoptosis. Under normal circumstances the proteasome clears
these ER aggregates, preventing cell death through this mechan-
ism. By blocking proteasome activity, bortezomib enhances
cytoplasmic fulvestrant-mediated ER aggregation, leading to
apoptotic cell death in a panel of ER-positive breast cancer cell
lines, a tamoxifen-resistant cell line in vitro, and also augments
tumor regression in a hormone resistant breast cancer xenograft
model.9 When bortezomib is added to fulvestrant, the nuclear
degradation of the ER is maintained. Bortezomib enhances the
efficacy of fulvestrant by promoting the novel effect of fulvestrant-
mediated ER aggregates in the cytoplasm.
On the basis of these observations, we initiated a hypothesis-
driven, randomized phase II open-label trial comparing fulvestrant
with fulvestrant plus bortezomib in postmenopausal women with
ER-positive metastatic breast cancer with disease that was
resistant to AI therapy, a common indication for fulvestrant
therapy.10 The primary trial endpoint was progression-free survival
(PFS), and we herein report the results of the primary analysis. A
secondary objective was to determine whether adding bortezo-
mib to fulvestrant produced clinical benefit in patients whose
disease progressed on the fulvestrant alone arm.
RESULTS
Patient characteristics
One hundred eighteen patients were enrolled from 17 institutions
between June 2010 and October 2013, including 59 patients
randomized to fulvestrant alone (arm A) and 59 patients
randomized to fulvestrant plus bortezomib (Arm B). Two patients
randomized to Arm B never received protocol therapy. Of 59
patients randomized to fulvestrant alone, Arm A, 27 (46%) crossed
over to receive fulvestrant plus bortezomib (Arm C) at progression
on fulvestrant alone.
The baseline characteristics of the 116 treated patients on arm A
and B, plus the 27 patients who crossed over from arm A to arm C
are shown are shown in Table 1. There were no significant
differences in patient characteristics between arms A and B with
regard to median age, Eastern Cooperative Oncology Group (ECOG)
performance status, prior chemotherapy for metastasis, average
prior lines of endocrine therapy (1.43 vs. 1.47), or liver metastases
(36 vs. 37%). Patients in arm A had longer median interval between
diagnosis and metastasis (49 vs. 28 months) and were more likely to
present with de novo metastatic disease (32 vs. 26%).
Efficacy
PFS rates at 12 months were 13.6% in arm A and 28.1% in arm B
(P= 0.03, 1-sided χ2-test; 95% confidence interval (CI) for
difference (14.5%) =− 0.06, 29.1%). PFS rates at 6 months were
28.8% in arm A versus 38.6% in arm B, respectively (P= 0.13 for
one-sided χ2-test). Although median PFS was similar in the two
arms (2.69 vs. 2.73 months, respectively), the hazard ratio for Arm
B versus Arm A (referent) was 0.73 (95% CI = 0.49, 1.09, P= 0.06,
one-sided log rank test) (Figure 1). This was significant at the
prespecified α ofo0.1.
We also compared the PFS in Arms A and B using the two-time
point test procedure as was pre-specified in the protocol.18 We
implemented the Mantel-Haenszel test procedure proposed by
Freidlin and Korn18 to adjust for the potential bias between
treatment arms due to subjective aspects coming from, for example,
as specified in ref. 18, ‘desire of the patient and treating physician to
get a patient on an active therapy regimen as quickly as possible.’ If
the two time points were chosen to be the median (month 2.71) and
twice the median (month 5.42) as suggested in Freidlin et al.18 the
two-sided test P-value was not significant (P=0.290). However, if we
chose the two time points to be months 6 and 12 given that the
patient follow-ups were at every 3 months after initiating treatment,
the two-sided test P-value was significant (P=0.059), which was
consistent with the significance from the log-rank test.
We used the reduced piecewise exponential estimate11 to
detect statistically significant changes in the hazard rate (risk) of
cancer progression in both arms. Then we compared the two arms
using the two-sample exact exponential test developed by
Table 1. Patient characteristics at registration
Arm A:
fulvestrant
alone
Arm B:
fulvestrant plus
bortezomib
Arm C:
crossover from
A to B
No. of treated
patients
59 57 27
Age
Median 57 years 59 years 57 years
Range 31–83 31–80 31–79
ECOG performance status
0 38 (64%) 37 (65%) 19 (70%)
1 20 (34%) 19 (33%) 7 (26%)
2 1 (2%) 1 (2%) 1 (4%)
Measurable disease
Yes 38 (64%) 31 (54%) 17 (63%)
No 21 (36%) 26 (46%) 10 (37%)
Metastatic disease sites
Bone 45 (76%) 46 (78%) 22 (81%)
Lung 23 (39%) 9 (15%) 9 (33%)
Liver 21 (36%) 22 (37%) 8 (30%)
Pleura 8 (14%) 5 (8%) 2 (76%)
Clinical presentation
Metastatic disease
at diagnosis
19 (32%) 15 (26%) 17 (63%)
Recurrence after
local regional
presentation
40 (68%) 42 (74%) 10 (37%)
Interval between diagnosis and metastasisa
Median 49.3 months 29.6 months 47.8 months
Mean 61.0 months 53.9 months 60.9 months
Prior systemic therapy for metastasis
Endocrine therapy 39 (66%) 42 (74%) 17 (63%)
Mean no. of prior
endocrine
therapies for
advanced disease
1.43 1.47
Chemotherapy 16 (27%) 17 (30%) 6 (22%)
Adjuvant
chemotherapy
32 (54%) 23 (40%) 13 (48%)
Adjuvant
Paclitaxel
18 (30%) 13 (23%) 8 (30%)
Adjuvant
Docetaxel
7 (23%) 1 (2%) 2 (7%)
Adjuvant
Taxane (sum of
paclitaxel and
docetaxel)
25 (42%) 14 (25%) 10 (37%)
Grade 1 Neuropathy
at registration
12 (20%) 12 (21%) 5 (19%)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
aIncludes only patients who presented with localized breast cancer and
had recurrence, including 40 patients in arm A, 42 in arm B and 10 patients
in arm C.
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Han et al12 which is the most power unbiased test. Comparing the
two arms for three time periods with constant failure rates (before
3 months, between months 3 and 9, and after 9 months), the two-
sided exact P-value from the two-sample exact exponential test
was 0.056, corresponding to the estimated failure rate of 0.167 in
Arm A and 0.077 in Arm B in the time period between 3 and
9 months. This analysis indicated that the failure rate in Arm B was
46% of that in Arm A after the first follow-up and before the third
follow-up. Thus, the log-rank test, the two time point test, and the
exact exponential test all showed that the patients in the
bortezomib-containing arm had improved PFS.
Of 27 patients randomized to fulvestrant alone (arm A) who
crossed over to fulvestrant plus bortezomib at progression (arm C),
clinical benefit occurred in 5 patients (18%) who were progression-
free for at least 24 weeks (Figure 2); this is consistent with the 17%
CBR rate that was prespecified as potentially promising. In addition,
as shown in Figure 2, PFS was substantially longer after crossover to
bortezomib than the initial period of PFS with fulvestrant
monotherapy in three patients, and three patients remained on
combination therapy after crossover at the time of the analysis.
At the time of the PFS analysis, median overall survival had not
yet been reached. Death had occurred in 20 of 59 patients (34%)
originally randomized to fulvestrant alone, and 15 of 57 patients
(26%) originally randomized to and treated with fulvestrant plus
bortezomib.
Treatment administered and adverse events
Patients received a total of 777 cycles of therapy, including 336
cycles on arm A (range 1–33), 333 on arm B (range 1–36), and 108
cycles on arm C (range 1–28). Of the 333 cycles of therapy given in
arm B, bortezomib was given at full dose on days 1, 8, and 15 in
294 (88%), 288 (86%), and 282 (95%) of the planned doses,
respectively. Bortezomib was discontinued due adverse events in
seven patients (12%) in arm B.
Adverse events (all grades) are summarized in Table 2. Adverse
events occurred more often in the bortezomib-containing arm, as
expected. The most common adverse events in the fulvestrant/
bortezomib combination arm compared with the fulvestrant alone
arm included nausea (63 vs. 29%), diarrhea (47 vs. 8%), sensory
neuropathy (46 vs. 29%), and limb edema (37 vs. 19%). Grade 3
events were uncommon, and there were no grade 4 or 5 adverse
events. Peripheral neuropathy observed in both arms at baseline
reflected prior taxane therapy and the trial eligibility criteria
allowed grade 1 neuropathy. However, post-treatment neuro-
pathy was higher in the bortezomib arm.
DISCUSSION
We performed a hypothesis-driven, randomized phase II trial of the
SERD fulvestrant alone or in combination with the proteasome
inhibitor bortezomib in 116 postmenopausal women with
ER-positive metastatic breast cancer who had progressive disease
after prior aromatase inhibitor therapy. Although previous studies
indicated that bortezomib was ineffective when used as mono-
therapy in patients with metastatic breast cancer,13,14 or in
combination with aromatase inhibitors,15 our trial design was
based upon evidence that the fulvestrant-bortezomib combination
exhibited synergistic antitumor activity in cell lines in vitro and a
mouse xenograft model.9 The addition of bortezomib to fulvestrant
significantly prolonged PFS, the prespecified primary endpoint,
resulting in a doubling of the PFS rate at 1 year to 28%, but did not
improve median PFS. The overall hazard ratio also favored the
combination. The addition of bortezomib to fulvestrant resulted in
disease stabilization for at least 24 weeks in 5 of 27 patients (18%)
who crossed over to the combination after disease progression on
prior fulvestrant monotherapy, providing an additional signal
supporting this combination. Adverse events including grade 1–2
Figure 1. Kaplan–Meier estimates of progression-free survival for
patients treated with fulvestrant (arm A) and fulvestrant plus
bortezomib (arm B).
Figure 2. Swimmers plot showing length of time on Arm A and Arm A for patients who crossed over.
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nausea, diarrhea, and neuropathy occurred more commonly in the
bortezomib-containing arm, but more serious events were uncom-
mon, and only 7 (12%) of patients discontinued bortezomib due to
adverse effects, suggesting a favorable therapeutic index for the
combination.
At the recommendation of the NCI/CTEP and in published
guidelines for randomized phase II clinical trials,16,17 we pre-
specified a statistical design that used a one-sided type I error rate
of 10% (Po0.1). This is based on the intent to keep patient
numbers reasonable in hypothesis generating phase II trials, the
goal of which is to identify promising regimens that warrant
further study, but not to provide definitive evidence of efficacy.16
In addition, our pre-specified statistical design required a test
suggested by Friedlin and Korn17,18 to eliminate bias that could be
introduced by imbalance in visit frequency between arm A (every
4 weeks) and arm B (weekly). Such analysis stipulated that we
would look at PFS rates at 6 and 12 months in accordance with
timing of imaging studies which were equivalent in both arms.
This analysis also demonstrated significance at the prespecified α
of o0.1. Finally, because our results suggested benefit for the
combination by the overall hazard ratio and in PFS rates at 1 year
but not in median PFS, we employed a post hoc two-sided
reduced piecewise exponential approach, with the goal of
determining whether clear differences in the fulvestrant only
and combination arms emerged within specific time periods. This
was also positive with two-sided P-value o0.1.
Table 2. Worst grade adverse events by treatment arm
CTC AE Term Fulvestrant Fulvestrant +Bortezomib
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Hematologic 21 (36%) 3 (5%) 0 (%) 27 (47%) 8 (14%) 0 (%)
Anemia 18 (31%) 1 (2%) 0 (%) 18 (32%) 5 (9%) 1 (2%)
Neutropenia 5 (8%) 0 (%) 0 (%) 16 (28%) 1 (2%) 0 (%)
Thromobycopenia 21 (36%) 3 (5%) 0 (%) 27 (47%) 8 (14%) 0 (%)
Metabolic
Hyperglycemia 22 (37%) 3 (5%) 1 (2%) 26 (46%) 3 (5%) 0 (%)
Hypoglycemia 2 (3%) 1 (2%) 0 (%) 6 (11%) 1 (2%) 0 (%)
SGOT_AST-High 12 (20%) 3 (5%) 0 (%) 13 (23%) 2 (4%) 2 (4%)
SGPT_ALT-High 6 (10%) 2 (3%) 0 (%) 12 (21%) 0 (%) 0 (%)
Hyponatremia 5 (8%) 0 (%) 0 (%) 6 (11%) 0 (%) 0 (%)
Gastrointestinal
Nausea 12 (20%) 4 (7%) 1 (2%) 23 (40%) 11 (19%) 2 (4%)
Vomiting 4 (7%) 3 (5%) 1 (2%) 11 (19%) 6 (11%) 1 (2%)
Diarrhea 4 (7%) 1 (2%) 0 (%) 14 (25%) 8 (14%) 5 (9%)
Constipation 18 (31%) 2 (3%) 0 (%) 19 (33%) 6 (11%) 1 (2%)
Dyspepsia 4 (7%) 2 (3%) 0 (%) 7 (12%) 3 (5%) 0 (%)
Anorexia 3 (5%) 6 (10%) 0 (%) 9 (16%) 4 (7%) 0 (%)
Neurologic
Headache 6 (10%) 1 (2%) 0 (%) 11 (19%) 3 (5%) 0 (%)
Pain 18 (31%) 14 (24%) 3 (5%) 16 (28%) 14 (25%) 1 (2%)
Neuropathy (Sensory) 17 (29%) 0 (%) 0 (%) 23 (40%) 3 (5%) 0 (%)
Mucocutaneous
Rash/desquamation 5 (8%) 0 (%) 0 (%) 6 (11%) 0 (%) 0 (%)
Injection Site Reaction 13 (22%) 1 (2%) 0 (%) 7 (12%) 0 (%) 0 (%)
Cardiopulmonary
Dyspnea 14 (24%) 4 (7%) 1 (2%) 7 (12%) 3 (5%) 1 (2%)
Cough 14 (24%) 2 (3%) 1 (2%) 11 (19%) 2 (4%) 0 (%)
Constitutional and Other
Fatigue 30 (51%) 2 (3%) 1 (2%) 20 (35%) 11 (19%) 1 (2%)
Limb edema 9 (15%) 2 (3%) 0 (%) 16 (28%) 5 (9%) 0 (%)
Fever 8 (14%) 1 (2%) 0 (%) 6 (11%) 1 (2%) 0 (%)
Insomnia 13 (22%) 2 (3%) 0 (%) 14 (25%) 5 (9%) 1 (2%)
Hot flashes 20 (34%) 2 (3%) 0 (%) 17 (30%) 1 (2%) 0 (%)
Dizziness 4 (7%) 0 (%) 0 (%) 10 (18%) 1 (2%) 0 (%)
Pruritis 4 (7%) 0 (%) 0 (%) 7 (12%) 2 (4%) 0 (%)
Rheumatologic
Arthralgia 15 (25%) 6 (10%) 0 (%) 11 (19%) 5 (9%) 0 (%)
Myalgia 4 (7%) 2 (3%) 0 (%) 6 (11%) 4 (7%) 0 (%)
Other
Anxiety 4(7%) 1(2%) 0(%) 8(14%) 3(5%) 0 (%)
Depression 3(2%) 2(3%) 0(%) 6(11%) 2(4%) 0 (%)
Othera,b
aThere was one grade 4 AST elevation in Arm B, which was unrelated to study drug.
bThere was one grade 5 cardiac arrest in Arm A, which was unrelated to study drug.
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The proteasome normally acts to limit the accumulation of
fulvestrant-induced ER aggregates and other toxic cytoplasmic
proteins. Our preclinical data demonstrated that the addition
of bortezomib to fulvestrant enhanced the accumulation of
ER aggregates in the cytoplasm, promoting induction of a
proapoptotic unfolded protein response, ultimately leading to cell
death.9 Fulvestrant's ability to degrade the ER in the nucleus is
well described, but its ability to promote aggregation of newly
synthesized ER in the cytoplasm has been largely overlooked. As
bortezomib does not block the degradation of the ER in the
nucleus but enhances the accumulation of ER-aggregates in the
cytoplasm, this strategy simultaneously exploits both effects of
fulvestrant on the ER. Resistance to endocrine therapy has been
categorized as primary, defined as disease progression within
6 months, or secondary, defined as disease progression occurring
after 6 months.3 Switching to an alternative endocrine therapy19
or chemotherapy may be appropriate in patients with either
primary or secondary resistance, depending on multiple factors
other than the resistance pattern.
Our population exhibited a high degree of primary resistance to
fulvestrant, as evidenced by the median PFS in both arms of
o3 months, which is similar to that seen in another trial of
women treated with fulvestrant after progression on an AI.20
Although the median PFS and 6-month PFS rates were similar in
the two arms, the 12-month PFS rate was two-fold higher for the
combination, suggesting that bortezomib did not impact primary
resistance to fulvestrant, but may delay the onset of acquired, or
secondary resistance. A potential explanation for this observation
is that in breast tumors with primary fulvestrant resistance, the
formation of aggregates alone may not be sufficient to induce cell
death. Two potential mechanisms support this: First, the level of
ER expression is likely to correlate with the ability of bortezomib to
mediate its synergistic effect, as previously shown in preclinical
models.21 As the threshold for the induction of the proapoptotic
unfolded protein response requires a minimum level of accumula-
tion of protein aggregates, it is likely that this threshold cannot be
reached in breast cancers that express low ER levels. In fact, low ER
expression has been shown to correlate with primary resistance to
fulvestrant.22 Second, elimination of protein aggregates by
autophagy provides an alternative mechanism to avoid the
induction of the pro-apoptotic unfolded protein response.23
Since this trial was initiated, CDK4/6 inhibition has emerged as
an important new therapeutic strategy for enhancing the
effectiveness of endocrine therapy, with a substantial impact in
abrogating primary resistance. The PALOMA 3 trial demonstrated
that the combination of the CDK4/6 inhibitor palbociclib with
fulvestrant significantly prolonged median PFS compared with
fulvestrant alone (median 3.8 vs. 9.2 months, HR 0.42,
Po0.0001).24 Nonetheless, acquired resistance eventually devel-
ops in most patients, and other therapeutic strategies are needed
to address this clinical problem. Preclinical cell line and xenograft
data in multiple myeloma suggest that palbociclib can enhance
the cytotoxic effects of bortezomib.25,26 A phase I/II study
demonstrated that the combination of palbociclib and bortezomib
can be safely co-administered.27 Given the complementary
mechanism of action of palbocilib and bortezomib, their impact
on different resistance patterns, and their safety when combined
in multiple myeloma, the combination of fulvestrant plus
palbocilib and bortezomib may warrant further evaluation in
preclinical models and carefully designed clinical trials.
In conclusion, our study supports the hypothesis that adding
bortezomib to fulvestrant likely enhances its effectiveness by
delaying or reversing acquired fulvestrant resistance. The results of
this trial provide a foundation for further exploration of the
combination of proteasome inhibitors with SERDs in postmeno-
pausal women with ER-positive metastatic breast cancer as a
strategy for addressing acquired resistance to fulvestrant-
containing endocrine regimens.
MATERIALS AND METHODS
Study design and treatment
This was an open-label, multicenter, randomized phase II trial. All patients
received fulvestrant (Faslodex, AstraZeneca Pharmaceuticals LP, Wilming-
ton, DE, USA) at a standard dose and schedule (500 mg IM days − 14, 1, 15
in cycle 1, and day 1 of each subsequent cycle). Patients were randomized
to Arm A (fulvestrant alone), or Arm B (fulvestrant plus bortezomib
(Velcade, Millennium, Boston, MA, USA)). Stratification factors at registra-
tion and randomization included ECOG performance status (0 vs. 1–2),
measurable disease (yes versus no), and prior chemotherapy for metastatic
disease (yes versus no). The bortezomib dose and schedule was 1.6 mg/m2
by rapid i.v. infusion over 3–5 seconds on days 1, 8, 15 of each 28-day cycle,
a schedule that was shown to be as effective and less toxic in multiple
myeloma than the biweekly dosing regimen.28 Fulvestrant was initiated two
weeks prior to the first dose of bortezomib to ensure adequate fulvestrant
blood levels prior to beginning bortezomib.29 Patients were allowed to
receive up to two doses of fulvestrant administered within a 4-week period
and not46 weeks prior to randomization. Concurrent treatment with bone
antiresorptive agents (e.g., bisphosphonates and denosumab) was permitted
for patients with bone metastases. Patients with progression on fulvestrant
alone (arm A) could cross over at progression to the fulvestrant plus
bortezomib combination (arm C). Treatment was continued without
interruption until disease progression, severe or intolerable toxicity, or
withdrawal of consent. The trial was reviewed, approved, and sponsored by
the Cancer Therapy Evaluation Program of the National Cancer Institute
(ClinicalTrials.gov, identifier NCT01142401) and coordinated by the New York
Cancer Consortium. The local institutional review board at each participating
institution approved the protocol. All patients gave written informed
consent.
Eligibility criteria
Postmenopausal women with histologically or cytologically confirmed
unresectable locally advanced or metastatic, ER-positive, Her2/neu
negative (as defined by local institutional laboratories) breast cancer with
measurable and/or non-measurable disease by RECIST 1.1 criteria were
eligible. Patients were required to have AI-resistant disease, defined either
as relapse while receiving adjuvant AI therapy and/or disease progression
after one or more AIs for metastatic disease. Patients were allowed to have
prior adjuvant chemotherapy, no more than one prior chemotherapy
regimen for metastatic disease and were required to have recovered from
prior neuropathy to grade 0–1. Other eligibility criteria included: age ⩾ 18
years, ECOG performance status of 0 to 2; adequate organ and marrow
function (leukocytes ⩾ 3,000/μl, absolute neutrophil count ⩾ 1,500/μl,
platelet count ⩾ 100,000/μl, total bilirubin ⩽ 2.0 mg/dl, AST and/or ALT
⩽ 2.5 × institutional upper limit of normal, serum creatinine ⩽ 1.5 mg/dl).
Tumor assessments, clinical evaluations, and dose modifications
All patients underwent computed tomography (CT) of the chest and
abdomen and a bone scan within 4 weeks of registration. Tumor response
was assessed every 12 weeks (±1 week) after cycle 1, day +1 by CT using
RECIST criteria version 1.1,30 and bone scans were repeated every 24 weeks
(±2 weeks). If the baseline bone scan showed metastases, and if the bones
were the only site of non-measurable disease, then bone scan was
repeated every 12 weeks (±1 week). Physician visits occurred on day 1 of
each cycle for patients in both arms. Adverse events were graded
according to the National Cancer Institute Common Terminology for
Adverse Events, version 4.0. For patients who experienced febrile
neutropenia, grade 4 toxicity hematologic toxicity, grade 2 neuropathy
(or grade 1 with pain), or other grade 3–4 non-hematologic toxicity, the
bortezomib dose was reduced, first to 1.3 mg/m2, then if recurrent to
1 mg/m2, and finally to 0.7 mg/m2. Fulvestrant was not held if bortezomib
was held for toxicity, and no dose reduction of fulvestrant was allowed.
Patients who stopped bortezomib due to severe or intolerable toxicity
continued fulvestrant alone until disease progression.
Primary and secondary study end points and statistical plan
The primary end point for the randomized phase II comparison of arm A
versus arm B was PFS, defined as time from cycle 1, day 1 of therapy to
disease progression or death from any cause. Clinical benefit rate (CBR)
was a secondary objective, and was defined as complete or partial
response, or stable disease (by RECIST 1.1) for at least 24 weeks. A sample
size of 118 (59 in each arm) was prespecified in order to provide sufficient
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power to detect a 70% improvement in median PFS from 5.4 to 9.0 months,
and compare PFS rates after 6 and 12 months (one-sided α=0.10, β=0.10),
with 100 PFS events required to perform the primary analysis. The PFS
distributions of the two treatment arms were estimated by Kaplan–Meier
survival analysis and compared by an unstratified log-rank test. Ninety-five
percent confidence intervals for the Kaplan–Meier PFS estimates were
calculated using Greenwood’s formulae. The primary comparison was made
using the intent-to-treat (ITT) patient population for all patients who received
at least one dose of fulvestrant. Because follow-up visit frequency differed
between the two treatment arms, a protocol-specified two time point
Mantel–Haenszel test procedure proposed by Freidlin et al18 was also used to
reduce evaluation-time bias that could be introduced when comparing PFS
between the two treatment arms.17 This technique was applied to test the
association of PFS and treatment arm status with the two time points
specified at the median and twice the median of the control arm (fulvestrant
alone), as well as at months 6 and 12. A reduced piecewise exponential
estimate11 was also used to fit the survival distribution in the two treatment
arms. The two arms were then compared in terms of the piecewise
exponential model parameters using a two-sample exact exponential test
given in ref. 12.
A secondary objective was to evaluate the CBR in patients who crossed
over from arm A (fulvestrant-alone) to arm C (fulvestrant+bortezomib) after
progression on fulvestrant alone. The crossover phase was designed to
distinguish between a CBR of 5 vs. 25% (α= 0.10, β= 0.10) using a Fleming
one-stage design. The regimen would be considered worthy of further
testing if at least 3 of 18 patients exhibited clinical benefit (i.e., CBR 17%).
This assumed that about 30% of patients on arm A would cross over to arm
C, although the actual crossover rate (27/59 (46%)) was higher than
projected.
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